Home  »  Business   »  We Analyzed the Future Direction of TScan Therapeu...

We Analyzed the Future Direction of TScan Therapeutics Inc. (TCRX), Here is What We Found

TScan Therapeutics Inc. (NASDAQ:TCRX) went down by -4.70% from its latest closing price compared to the recent 1-year high of $5.60. The company’s stock price has collected -3.23% of loss in the last five trading sessions.

Is It Worth Investing in TScan Therapeutics Inc. (NASDAQ :TCRX) Right Now?

Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for TScan Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $14.00, which is $12.0 above the current price. TCRX currently public float of 17.61M and currently shorts hold a 0.84% ratio of that float. Today, the average trading volume of TCRX was 26.68K shares.

TCRX’s Market Performance

TCRX stocks went down by -3.23% for the week, with a monthly jump of 25.00% and a quarterly performance of -36.94%, while its annual performance rate touched -56.52%. The volatility ratio for the week stands at 16.67% while the volatility levels for the past 30 days are set at 16.82% for TScan Therapeutics Inc. The simple moving average for the period of the last 20 days is 10.79% for TCRX stocks with a simple moving average of -27.62% for the last 200 days.

TCRX Trading at -3.06% from the 50-Day Moving Average

After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.24% of loss for the given period.

Volatility was left at 16.82%, however, over the last 30 days, the volatility rate increased by 16.67%, as shares surge +20.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.23% lower at present.

During the last 5 trading sessions, TCRX fell by -6.82%, which changed the moving average for the period of 200-days by -26.52% in comparison to the 20-day moving average, which settled at $1.82. In addition, TScan Therapeutics Inc. saw 35.48% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TCRX starting from Silver Brian M., who purchase 3,158 shares at the price of $1.56 back on Dec 28. After this action, Silver Brian M. now owns 32,885 shares of TScan Therapeutics Inc., valued at $4,941 using the latest closing price.

Silver Brian M., the Chief Financial Officer of TScan Therapeutics Inc., purchase 2,842 shares at $1.50 during a trade that took place back on Dec 27, which means that Silver Brian M. is holding 29,727 shares at $4,276 based on the most recent closing price.

Stock Fundamentals for TCRX

Current profitability levels for the company are sitting at:

  • -479.65 for the present operating margin
  • +67.18 for the gross margin

The net margin for TScan Therapeutics Inc. stands at -479.49. Equity return is now at value -44.50, with -36.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 7.76.